Amgen Inc. (AMGN): A Bull Case Theory
We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.
Amgen Inc (AMGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 96,060 | $29,927,557 | -31% | 0.26% |
| 2. | ARK Investment Management Catherine D. Wood | 59,031 | $18,391,188 | -12% | 0.18% |
| 3. | Levin Easterly Partners John Murphy | 54,716 | $17,046,770 | +5% | 1.42% |
| 4. | Bailard Inc Thomas Bailard | 46,533 | $14,497,356 | +3% | 0.37% |
| 5. | Bourgeon Capital John Zaro | 39,674 | $12,360,567 | -1% | 2.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.50 | 10 | Director | 3,582 | 2015-08-19 | Filing | |
| $166.64 | 3,000 | Director | 3,572 | 2015-08-19 | Filing | |
| $152.29 | 1,500 | Director | 2,000 | 2015-02-05 | Filing | |
| $152.29 | 1,500 | Director | 2,000 | 2015-02-05 | Filing | |
| $111.77 | 894 | Officer, Director | 185,013 | 2014-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $279.69 | 1,000 | Officer | 4,034 | 2025-05-02 | Filing | |
| $292.84 | 8,711 | Officer | 71,546 | 2025-02-19 | Filing | |
| $304.44 | 25,225 | Officer | 36,922 | 2025-02-21 | Filing | |
| $293.22 | 8,711 | Officer | 62,147 | 2025-02-19 | Filing | |
| $293.74 | 1,524 | Officer | 8,544 | 2025-02-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 52,870,453 | $16,471,789,632 | 0.3% | |
| 2. | 45,439,431 | $14,156,654,926 | 0.3% | |
| 3. | 12,388,295 | $3,859,573,309 | 3.19% | |
| 4. | 12,205,942 | $3,802,761,230 | 0.71% | |
| 5. | 4,454,164 | $1,387,695,048 | 0.22% |
News See All
The Best and Worst Dow Stocks
It also acts as a reference point for analysts and investors. However, not all stocks within this elite group of companies perform equally.
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Call Transcript
Operator: My name is Julianne and I'll be your conference facilitator today for the Amgen Q1 FY 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
The Best and Worst Dow Stocks for the Next 12 Months
The Dow Jones Industrial Average (DJIA), or the Dow, is a price-weighted index that has long been seen as a barometer of the health of the U.S. economy.
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds
On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech sector could be heading into a period of major volatility.
10 Innovative Healthcare Stocks to Watch in 2025
In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.
13 Best Healthcare Dividend Stocks to Invest in
The US healthcare sector has been at the forefront since the emergence of COVID-19 in 2020, leading to a significant transformation in the industry.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Dobermans of the Dow: 10 Stocks to Consider
The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the Dow approach, offering a more selective screening process.